Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24117380 | 0.93 | PDPK1 (0.36) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL12874831 | 0.78 | PDE4A (0.41) | DYRK1AGSK3BKCNH2RETKDR | |
| SCHEMBL12874842 | 0.77 | DYRK1A (0.62) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL24117382 | 0.72 | NFATC1 (0.35) | DYRK1ANFATC1GSK3B | |
| SCHEMBL24117379 | 0.66 | NFATC1 (0.50) | DYRK1ANFATC1GSK3B | |
| SCHEMBL16640342 | 0.65 | CDK4 (0.41) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL820570 | 0.64 | DYRK1A (0.47) | DYRK1AGSK3B | |
| SCHEMBL16019431 | 0.64 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL12874893 | 0.64 | NPC1 (0.44) | — | |
| SCHEMBL18993230 | 0.64 | DYRK1A (0.49) | DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DYRK1A 4407/4885NFATC1 1132/4885GSK3B 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.